Abbott Laboratories vs Merck & Company at a glance
Both companies operate in the Health Care sector, so these figures are broadly like-for-like.
| Metric | ABT | MRK |
|---|---|---|
| Market cap | $203.36B | $372.43B |
| Price | $116.13 | $156.45 |
| P/E ratio (TTM) | 33.47 | 14.18 |
| P/B ratio (MRQ) | 4.19 | 4.92 |
| P/S ratio (TTM) | 4.93 | 3.98 |
| Revenue growth (1Y) | 5.67% | 1.31% |
| Return on equity (TTM) | 12.51% | 34.70% |
| Return on invested capital (TTM) | 9.36% | 22.71% |
| Gross margin (TTM) | 56.80% | 82.44% |
| Net margin (TTM) | 11.65% | 13.59% |
| Dividend yield (TTM) | 2.16% | 2.26% |
How they differ
Merck & Company is the larger company at $372.43B versus $203.36B — about 1.8x the size.
On trailing earnings, Merck & Company is the cheaper of the two at 14.18 against 33.47 for Abbott Laboratories.
On sales, Merck & Company is the cheaper of the two at 3.98 against 4.93 for Abbott Laboratories.
Abbott Laboratories leads on revenue growth over the past year, 5.67% against 1.31%.
Merck & Company leads on return on invested capital, 22.71% against 9.36%.
Merck & Company leads on gross margin, 82.44% against 56.80%.
Merck & Company offers the higher yield at 2.26% against 2.16%.
Go deeper
Ratios describe the past. Whether either is worth owning depends on what you pay today.
Related comparisons
Other matchups involving Abbott Laboratories or Merck & Company.